Sponsors
Biomedcode Hellas is a leading Contract Research Organization (CRO) specializing in advanced preclinical drug evaluation, and we are honored to welcome them as a Silver Sponsor at our conference. Founded as a spin-off of the BSRC “Alexander Fleming”, Biomedcode combines strong academic roots with cutting-edge biotechnology expertise, offering a powerful platform for therapeutic discovery and development.
​
The company is internationally recognized for its unique collection of humanized transgenic mouse models, designed to accurately reproduce key mechanisms of human disease. These proprietary models—including those targeting TNF, IL-17, RANKL, IL-23, and other clinically relevant pathways—enable high-precision testing of candidate therapeutics under physiologically meaningful conditions. Their portfolio covers a wide spectrum of disease areas, such as acute and chronic inflammation, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, osteoporosis, and more.
​
Biomedcode’s preclinical services are built upon standardized, validated procedures and backed by advanced laboratory infrastructure operating under SPF (Specific Pathogen Free) conditions. Their workflows integrate in vivoefficacy studies, histopathology, pharmacokinetics/pharmacodynamics (PK/PD), as well as complementary in vitrocellular and molecular assays. With an exceptional team of experienced scientists, they deliver customized study designs tailored to the specific needs of pharmaceutical and biotechnology partners worldwide, ensuring reliable, reproducible, and translatable results.
​
Alongside routine service provision, Biomedcode maintains a dynamic Research & Development program, continuously expanding and refining their humanized mouse platforms to address emerging therapeutic targets and unmet medical needs. Their strong emphasis on innovation, scientific rigor, and customer-oriented support positions Biomedcode as a major contributor to the advancement of biomedical research and drug development.
We are delighted to have Biomedcode as a sponsor, and we look forward to their continued impact on the global scientific and biopharmaceutical community.
The Menarini Group is a globally respected pharmaceutical and diagnostics company with more than 135 years of history, and we are proud to have them as a gold sponsor at our conference. Headquartered in Florence, Italy, Menarini has built an international presence in over 140 countries, supported by approximately 17,000 employees.
​
From its origins in 1886, Menarini has grown into a diversified healthcare organization, investing heavily in research and development across several key therapeutic areas, including oncology, cardiology, inflammation, respiratory disease, and anti-infectives. One of Menarini’s core strengths lies in its R&D network, which comprises nine research centers worldwide working on both small-molecule drugs and biologics. Their pipeline spans innovative platforms, from targeted cancer therapies to anti-infectives and advanced diagnostic solutions.
​
Moreover, Menarini includes the Menarini Biotech division, a fully integrated CDMO (Custom Development & Manufacturing Organization) based in Italy. With nearly 20 years of experience, Menarini Biotech supports biopharmaceutical development from candidate selection through GMP manufacturing, offering scalable technologies and quality systems aligned with global regulatory standards.
​
Sustainability and ethical innovation are central to Menarini’s mission. According to their 2023 corporate report, they are committed to environmental stewardship, responsible growth, and advancing unmet medical needs in a patient-centered way.
In summary, Menarini’s long-standing heritage, global reach, scientific leadership, and commitment to innovation make them a cornerstone of the pharmaceutical industry — and a valued partner in the biomedical community. We are very pleased to welcome Menarini Group as a distinguished sponsor of our conference.